Video Debriefing at the Delivery Ward

May 9, 2023 updated by: University of Aarhus

Video Debriefing at the Delivery Ward - Empowering Obstetric Teams to High Performance

Postpartum hemorrhage continues to be the leading cause of maternal morbidity and mortality worldwide. Successful management of postpartum hemorrhage requires not only administration of the right medicine, but also a rapid and coordinated response from a multi-professional team. A prerequisite for this is that the individuals are well trained, which the investigators believe can be improved by video debriefing of real-life events.

The purpose of this study is to improve obstetric teams management of postpartum hemorrhage using video recordings of real-life events in post event debriefings.

Cameras are placed in the ceiling of all delivery rooms to record obstetric teams' management of postpartum hemorrhage. Video recording requires informed consent from all participants. After an event, the team will review their own performance on video in a debriefing session to improve future performance.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Background:

Video review was first introduced in healthcare in the 1980s to improve emergency teams' management of critical situations by having them review their own performance on video in a debriefing session. Video debriefing offers an opportunity to review the care delivered in high-stake, high-risk, and time-critical situations. Video debriefing has been found to improve the performance of neonatal resuscitation teams and trauma teams; however, video debriefing has not generally been accepted in the delivery ward. A recent PhD project developed a method for systematically filming obstetric emergencies, in two Danish hospitals, where informed consent had been obtained from all participants. In addition, the project developed a method for systematically assessing obstetric teams' clinical performance during postpartum hemorrhage

The aim of the study is to examine the effect of real-life video debriefing on obstetric teams' management of major postpartum hemorrhage.

Material and methods:

The study will be conducted at two Danish hospitals, Aarhus University Hospital (5,000 deliveries per year) and Horsens Regional Hospital (2,300 deliveries per year).

All delivery rooms have been equipped with an automatic recording system that enables filming of all postpartum hemorrhage. Video recording requires informed consent from all participants. Women expecting to deliver will be invited to provide informed consent for video recording. If a woman declines the invitation, the cameras will be covered up according to our protocol. If video recording occurs, all participants will be asked to give informed consent again.

Video debriefing will be conducted by educated facilitators of debriefing. Debriefings will follow a protocol and will focus on teams' clinical performance and non-technical skills. The main focus of the debriefing protocol will be clinical debriefing with a main goal of improving clinical performance and patient care.

Videos will be included as follows: 1) Baseline video inclusion, before introducing real-life video debriefings of team performance; 2) During the start-up of the debriefings in an exploratory study; 3) After real-life video debriefings have been introduced as standard procedure.

Perspectives:

This project is the first to evaluate the implementation, feasibility and use of real-life video debriefing in obstetric care. Results from this project can revolutionize the ability to learn from clinical cases and can guide how video can be introduced in ways acceptable to women, relatives and healthcare providers.

Study Type

Interventional

Enrollment (Actual)

420

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus N, Denmark, 8200
        • Aarhus University Hospital
      • Horsens, Denmark, 8700
        • Horsens Regional Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Women with major postpartum hemorrhage (1.0 liter or more).

Exclusion Criteria:

  • Language difficulties requiring an interpreter or translator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention - Video debriefing
Baseline period (year 1): Standard practice. Intervention period (year 2-3): All teams will be assigned to video debriefing.
Obstetric teams will review their own performance on video in a debriefing session to improve future performance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical performance
Time Frame: All videos will be assessed 2.5 years (autumn 2023)
Videos will be assessed by raters using the TeamOBS-PPH checklist (Brogaard L et al, Development of the TeamOBS-PPH - targeting clinical performance in postpartum hemorrhage, 2018)
All videos will be assessed 2.5 years (autumn 2023)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Non-technical performance
Time Frame: All videos will be assessed 2.5 years (autumn 2023)
Videos will be assessed by raters using the AOTP checklist.
All videos will be assessed 2.5 years (autumn 2023)
Maternal birth characteristics. Time of day.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Day/Night
Data will be assessed 2.5 years (autumn 2023)
Maternal birth characteristics. Blood loss.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Total blood loss (ml)
Data will be assessed 2.5 years (autumn 2023)
Maternal birth characteristics. GA.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Gestational age
Data will be assessed 2.5 years (autumn 2023)
Maternal birth characteristics. Birth length (>18 hours).
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Yes/No
Data will be assessed 2.5 years (autumn 2023)
Maternal birth characteristics. Epidural
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Yes/No
Data will be assessed 2.5 years (autumn 2023)
Maternal birth characteristics. Oxytocin.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Yes/No
Data will be assessed 2.5 years (autumn 2023)
Maternal birth characteristics. Induction.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Yes/No
Data will be assessed 2.5 years (autumn 2023)
Maternal birth characteristics. Twin pregnancy.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Yes/No
Data will be assessed 2.5 years (autumn 2023)
Maternal characteristics additional. Age.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Years
Data will be assessed 2.5 years (autumn 2023)
Maternal characteristics additional. BMI.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- BMI
Data will be assessed 2.5 years (autumn 2023)
Maternal characteristics additional. Previous postpartum hemorrhage.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Yes/No
Data will be assessed 2.5 years (autumn 2023)
Maternal characteristics additional. Previous births
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Number
Data will be assessed 2.5 years (autumn 2023)
Team characteristics. Team size.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Number of team members involved
Data will be assessed 2.5 years (autumn 2023)
Team characteristics. Hospital.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Regional / University
Data will be assessed 2.5 years (autumn 2023)
Neonatal characteristics. Mean birth weight.
Time Frame: Data will be assessed 2.5 years (autumn 2023)
- Grams
Data will be assessed 2.5 years (autumn 2023)
Implementation of video debriefing
Time Frame: Data will be assessed 2.5 years (autumn 2023)
Number of debriefing sessions performed (in total / per participant / failed attempted sessions).
Data will be assessed 2.5 years (autumn 2023)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2020

Primary Completion (Actual)

December 31, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

November 12, 2020

First Submitted That Met QC Criteria

November 20, 2020

First Posted (Actual)

November 30, 2020

Study Record Updates

Last Update Posted (Estimate)

May 11, 2023

Last Update Submitted That Met QC Criteria

May 9, 2023

Last Verified

September 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The final dataset will be publicly available in an anonymized form using an open data repository.

IPD Sharing Time Frame

Study protocol is available at the projects homepage www.teamobs.dk.

Trial related documents and data will be available when results are published and until three years after publication of the last study results.

IPD Sharing Access Criteria

Interested parties will be able to request the data by contacting the trial sponsor.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postpartum Hemorrhage

Clinical Trials on Video debriefing

Subscribe